Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 antibody + anlotinib with metronomic chemotherapy in advanced triple-negative breast cancer
ChiCTR2100044725Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of PD-1 Monoclonal Antibody and anlotinib in triple-negative breast cancer (TNBC), sponsored by Shandong Cancer Hospital. Primary endpoints: objective remission rate, disease control rate and 1 more. Started Oct 2020; status: recruiting.
02
Drugs
PD-1 Monoclonal Antibodyanlotinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2100044725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044725.